Document resource
Background and Importance Atopic dermatitis (AD) is a chronic inflammatory skin disease with heterogeneous clinical manifestations depending on age and severity. It typically follows a relapsing course characterised by intense pruritus and eczematous lesions. Beyond skin involvement, AD affects patients’ quality of life(QoL) due to persistent itching and sleep disturbances among other factors. According to national guidelines, therapeutic positioning of biological therapies (BT) remains uncertain.Aim and Objectives The primary objective was to assess QoL of patients with moderate-to-severe AD treated with dupilumab or tralokinumab that were attended in pharmaceutical care consultations (PCC) and to analyse differences between the two treatment groups. Secondary objective was to compare the rate of treatment switching to another BT between the above groups of treatment.Material and Methods A multicentre, observational, retrospective study was conducted including patients with AD treated with dupilumab or tralokinumab for at least 3 months that were attended in PCC at the participating centres. Sociodemographic characteristics were collected from medical records (age, sex, obesity). QoL was assessed using the Dermatology Life Quality Index (DLQI), while pruritus and sleep quality were measured through the Numerical Rating Scale (NRS). Questionnaires were collected during PCC, either in paper format or through a pseudonymised QR code. Ordinal-variables were analysed using Mann–Whitney-U test and categorical variables by χ 2-test (p< 0.05). Data were analysed using SPSSv27.Results 35 patients were analysed. The 54.3% were male. The mean age (years) was 40.6 (DE±16). The 65.7% were treated with dupilumab and 34.3% received tralokinumab. The 14.8% were obese (BMI>30Kg/m2).QoL results Dupilumab group:– DLQI: no effect(43.5%), mild (26.1%), moderate (21.7%), severe (8.7%)– Pruritus NRS: no impact (17.4%), mild (56.5%), moderate (21.7%), severe (4.3%)– Sleep NRS: no impact (43.5%), mild (47.8%), moderate (4.3%), severe (4.3%) Tralokinumab group:– DLQI: no effect (16.7%), mild (25.0%), moderate (33.3%), severe (25.0%)– Pruritus NRS: no impact (0%), mild (33.3%), moderate (41.7%), severe (16.7%), very severe (8.3%)– Sleep NRS: no impact (0%), mild (75.0%), moderate (8.3%), severe (16.7%)Statistically significant differences were observed in pruritus NRS (p=0.014) and sleep NRS (p=0.017).No statistically significant differences were observed concerning DLQI scores.Treatment switching occurred in 17.1% of the overall study population: 17.4% in dupilumab group and 16.7% in tralokinumab group.No statistically significant differences were observed in treatment switching between tralokinumab and dupilumab.Conclusion and Relevance Patients treated with dupilumab reported significantly greater QoL with regard to pruritus and sleep outcomes compared with those treated with tralokinumab.Conflict of Interest No conflict of interest